The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Région wallonne; Prov. Brabant wallon; Arr. Nivelles
Location of affected unit(s)
Rixensart
Sector
Manufacturing (20 - 21) Manufacture of chemicals and pharmaceuticals 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
386 jobs Number of planned job losses
Announcement Date
5 February 2020
Employment effect (start)
1 March 2020
Foreseen end date
Description
GlaxoSmithKline (GSK), a multinational pharmaceutical company, has announced a worldwide restructuring measure with direct repercussions for its facilities in Belgium, including globally its biggest centre of vaccine production. The company has indicated its intention to split up its different divisions into separate companies. The vaccine production facility in Rixensart will be automated in the coming years, requiring less employees to maintain production. The company has announced that 720 employee posts are at risk in the announced restructuring as well as 215 temporary posts. The majority of those affected will be white-collar workers. The restructuring measures are alarming as GSK is the largest private employer within the entire Walloon region. Trade unions were aware of the possibility of restructuring and job loss.They are however worried that more dismissals will follow in the future.
Update 30/9/20: At the end of September the company announced that after negotiations with the trade unions (as stipulated in the 'Renault-Law') the amount of dismissals that will ultimately take place have been reduced to 386 instead of 720.
Eurofound (2020), GlaxoSmithKline, Internal restructuring in Belgium, factsheet number 99738, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/99738.
Eurofound’s ERM restructuring legislation database offers an overview of key restructuring-related regulations in the EU Member States and Norway. Its content is continuously updated to reflect any changes made by national legislators in response to, for instance, policy shifts, legal...
Can Europe still achieve its ambitions for battery manufacturing? To answer this, the article looks at data from Eurofound’s European Restructuring Monitor and explores what recent large-scale restructuring events reveal about the state of play in the EU battery sector.
This working paper offers a comprehensive methodological overview of the European Restructuring Monitor (ERM) databases. Even though the methodology has not changed over time, new categories have been added, and the way it has been used by researchers and policymakers...
This Eurofound research paper explores key trends in restructuring in recent years, highlighting the companies that announced the largest job losses and job gains in the EU. It builds on an analysis of company announcements recorded in Eurofound’s European Restructuring...
In 2023, thousands of workers in big tech lost their jobs. Meta, Amazon, Google, Apple, Microsoft and Salesforce had been considered to offer good and secure jobs up to this point. Giants of the information and communication technology (ICT) sector,...
In 2024, the automotive sector in the EU came to the fore in public and policy discussions. The focus was on the slowdown in electric vehicle (EV) sales, rising global competition, belated investments in new technologies, and the potential closure...